Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
Gwechenberger M, Barón-Esquivias G, de Vries TAC, Siller-Matula JM, Manu MC, Souza JAG, Wienerroither S, Pecen L, de Groot JR, De Caterina R, Kirchhof P; ETNA-AF-Europe Investigators. Gwechenberger M, et al. Among authors: baron esquivias g. JACC Adv. 2024 Mar 11;3(4):100880. doi: 10.1016/j.jacadv.2024.100880. eCollection 2024 Apr. JACC Adv. 2024. PMID: 38939675 Free PMC article.
Rhythm versus rate control in patients with newly diagnosed atrial fibrillation - Observations from the GARFIELD-AF registry.
Pope MK, Hall TS, Virdone S, Atar D, John Camm A, Pieper KS, Jansky P, Haas S, Goto S, Panchenko E, Baron-Esquivias G, Angchaisuksiri P, Kakkar AK; GARFIELD-AF Investigators. Pope MK, et al. Among authors: baron esquivias g. Int J Cardiol Heart Vasc. 2023 Nov 16;49:101302. doi: 10.1016/j.ijcha.2023.101302. eCollection 2023 Dec. Int J Cardiol Heart Vasc. 2023. PMID: 38020059 Free PMC article.
Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
Rivera-Caravaca JM, Anguita Sanchez M, Sanmartín Fernández M, Rafols C, Barón-Esquivias G, Arribas Ynsaurriaga F, Freixa-Pamias R, Lekuona Goya I, Vázquez Rodríguez JM, Pérez-Cabeza AI, Cosín-Sales J, Ureña Montilla I, Álvarez-Vieitez Blanco A, Marín F. Rivera-Caravaca JM, et al. Among authors: baron esquivias g. Am J Cardiol. 2023 Sep 15;203:122-127. doi: 10.1016/j.amjcard.2023.06.105. Epub 2023 Jul 22. Am J Cardiol. 2023. PMID: 37487406 Free article.
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxaban.
Marín F, Fernández MS, Barón-Esquivias G, Barrios V, Lekuona I, Pérez-Cabeza AI, Masjuan J, Del Vigo ER, Vázquez Rodríguez JM, Freixa-Pamias R, Schilling VR, Arribas F, Priu CR, Sánchez MA. Marín F, et al. Among authors: baron esquivias g. J Comp Eff Res. 2023 Mar;12(3):e220049. doi: 10.57264/cer-2022-0049. Epub 2023 Feb 7. J Comp Eff Res. 2023. PMID: 36749006 Free PMC article.
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
Anguita Sánchez M, Marín F, Masjuan J, Cosín-Sales J, Vázquez Rodríguez JM, Barrios V, Barón-Esquivias G, Lekuona I, Pérez-Cabeza AI, Freixa-Pamias R, Parra Jimenez FJ, Monzer Khanji Khatib M, Rafols Priu C, Sanmartín Fernández M. Anguita Sánchez M, et al. Among authors: baron esquivias g. Cardiol J. 2022;29(6):936-947. doi: 10.5603/CJ.a2022.0091. Epub 2022 Oct 6. Cardiol J. 2022. PMID: 36200548 Free PMC article.
Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.
Marin F, Fernández MS, Lekuona I, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Freixa-Pamias R, Masjuan J, Pérez-Cabeza AI, Schilling VR, Vázquez Rodríguez JM, Priu CR, Sánchez MA. Marin F, et al. Among authors: baron esquivias g. J Comp Eff Res. 2022 Nov;11(16):1173-1184. doi: 10.2217/cer-2022-0111. Epub 2022 Sep 23. J Comp Eff Res. 2022. PMID: 36148923 Free article.
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
Sanmartín Fernández M, Anguita Sánchez M, Arribas F, Barón-Esquivias G, Barrios V, Cosin-Sales J, Esteve-Pastor MA, Freixa-Pamias R, Lekuona I, Pérez-Cabeza AI, Ureña I, Vázquez Rodríguez JM, Rafols Priu C, Marin F. Sanmartín Fernández M, et al. Among authors: baron esquivias g. Cardiol J. 2022;29(4):601-609. doi: 10.5603/CJ.a2022.0044. Epub 2022 May 27. Cardiol J. 2022. PMID: 35621092 Free PMC article.
Predicted Value of MicroRNAs, Vascular Endothelial Growth Factor, and Intermediate Monocytes in the Left Adverse Ventricular Remodeling in Revascularized ST-Segment Elevation Myocardial Infarction Patients.
Del Toro R, Galeano-Otero I, Bevilacqua E, Guerrero-Márquez F, Falcon D, Guisado-Rasco A, Díaz-de la Llera L, Barón-Esquivias G, Smani T, Ordóñez-Fernández A. Del Toro R, et al. Among authors: baron esquivias g. Front Cardiovasc Med. 2022 Mar 24;9:777717. doi: 10.3389/fcvm.2022.777717. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35402537 Free PMC article.
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR study.
López-Gálvez R, Rivera-Caravaca JM, Anguita Sánchez M, Sanmartín Fernández M, Rafols C, Pérez-Cabeza AI, Barón Esquivias G, Lekuona Goya I, Vázquez Rodríguez JM, Cosín Sales J, Arribas Ynsaurriaga F, Barrios V, Freixa-Pamias R, Marín F. López-Gálvez R, et al. Among authors: baron esquivias g. Eur J Clin Invest. 2022 Sep;52(9):e13788. doi: 10.1111/eci.13788. Epub 2022 Apr 14. Eur J Clin Invest. 2022. PMID: 35395094
97 results